Amelia is a four-time UK biotech CFO whose career has tracked oncology and platform therapeutics from seed to Series C. She led the Series A at Stellaris Bio from inside the company, ran a portfolio CFO mandate across Northlight Genomics, and most recently took Helix Therapeutics from pre-Series A through a £58m Series C. With the Helix build now mature and her pattern historically being two- to three-year early-stage tours, she is a natural fit for a pre-Series A oncology CFO seat where the work is fundraise, board, and function-build from scratch.

Daniel is a four-time UK biotech CFO with a co-founder credit, now sitting as MD at Kestrel Biopharma after building and leading finance at Glasslake, Cantor and Halcyon. His career has tracked the Cambridge oncology cluster almost exclusively, with hands-on Series A leadership, R&D tax credit and EIS/SEIS work, and a target-side trade sale at Halcyon. For a NorthVale brief that asks for a CFO who has done this exact motion before, he is as close to a template match as the UK market produces.

Priya is a UK biotech finance lifer with an unusually clean sector focus — every operating role since Yarrowfield has been in drug development, and the last three have been Oxford- or Cambridge-cluster oncology and rare disease companies. She stepped into the interim CFO seat at Tessera Therapeutics UK to run their Series A extension, then moved to Embercast Bio as SVP Finance with a clear succession into the CFO chair that hasn't yet materialised. Her track record covers target-side M&A (Brookmere's acquisition), Series A/B fundraises, and standing up finance functions from a single bookkeeper. For a pre-Series A oncology CFO brief in the UK, she is as close to a templated match as the market produces.

Henry is a four-time UK biotech CFO who has run the full pre-seed-to-Series-B arc inside drug-development companies, most recently at Selwyn Biotech and before that Drumlin Therapeutics where he led a £22m Series A end-to-end. His career has been deliberately confined to UK therapeutics — Calderwood, Larchmont, Drumlin, Selwyn — with a NED and then Chair seat at Faraway Pharma adding target-side M&A exposure through its trade sale. For a NorthVale brief that demands UK ecosystem fluency, Series A leadership from the inside, and the temperament to build a finance function from a standing start, he is the cleanest profile we have seen this cycle.

Isabel is a four-time UK biotech CFO with a career built almost entirely inside venture-backed drug-development companies, from early seed work at Arclight Pharma through to a £28m Series A close at Verdant Biosciences and a Series B at Northlight Genomics. Her current seat at Quintile Bio is a pre-Series A oncology platform — a near-identical shape to the NorthVale brief — and she supplements it with an audit chair role at Stellaris Bio and an earlier executive director stint at Helix Therapeutics. She is Edinburgh-based, deeply networked with Scottish Enterprise, Cambridge Innovation Capital and the usual UK life sciences VCs, and has built finance functions from a single bookkeeper upward more than once. For a CFO search where UK biotech tenure is non-negotiable, she is exactly the archetype.

Marcus is a career UK biotech CFO whose arc runs from interim work at Ridgeline Bio, through founding Cantor Pharma as an advisory vehicle, into three consecutive permanent CFO seats at Glasslake, Kestrel and now Meridian — each one an oncology or oncology-adjacent drug developer. He led the £18m Glasslake Series A and the £34m Kestrel Series B from inside the company, and was target-side principal on the Halcyon trade sale to a US mid-cap. FCMA-qualified, deeply networked across the Cambridge and Oxford VC bench, and credible with HMRC on R&D claims north of £2m. For a NorthVale-stage Series A, he is overqualified on paper but the timing at Meridian and his stated preference for the build phase make the conversation live.

Sofia is a career UK biotech CFO with four sitting-CFO appointments and two earlier Finance Director roles, every one of them inside drug-development companies. She led the Series A at Stellaris Bio (£18m, Abingworth-led) and the Series A extension at Wintergreen, built finance functions from a blank page at Linden Pharma and Stellaris, and currently runs finance at Saltford Pharma through its Series B preparation. For a UK pre-Series A oncology CFO brief, her profile is essentially the reference specification — the only real question is whether she's movable.

Olivia is a Cambridge-based biotech CFO with a decade of UK drug-development finance behind her, having moved from subsidiary controller work at Drumlin Therapeutics through commercial finance at Selwyn Biotech into progressively senior roles at Carrick Pharma, where she ultimately led the Series A as CFO. She is currently CFO at Iverline Bio, again in oncology, and has run the full UK toolkit — R&D tax credits, EIS/SEIS, HMRC advance assurance, and the Cambridge VC circuit. For a pre-Series A oncology biotech CFO mandate, she is effectively a like-for-like profile, with the caveat that she will need to be persuaded to leave a seat she only took two years ago.

Jonas is an FCA-qualified biotech CFO with two decades inside UK drug-development companies, almost entirely in the Oxford and Cambridge clusters. He built finance from scratch at Helix Therapeutics and Ashstone Biopharma, led the Series A at both, and then stepped up to a group CFO seat at Faraway Pharma after Calderwood's trade sale. The interesting wrinkle for this brief is that his recent activity — the Larchmont chairmanship, the Quintile Bio consulting stint between executive roles — suggests he prefers the pre-Series A texture to the group-reporting world he now inhabits.

Clara is a career UK biotech CFO with a clean oncology and therapeutics thread running from Kestrel Biopharma through Solivant Therapeutics to her current interim seat at Verdant Biosciences. She has led a Series A from inside the company, sits on two biotech boards as audit chair, and has run finance functions from a blank sheet twice. The interim posture at Verdant and the recent NED appointment at Arclight suggest she is actively shaping her next permanent move, which makes the timing on this brief unusually clean.